Five Prime Therapeutics Inc (FPRX) Expected to Post Quarterly Sales of $4.81 Million

Share on StockTwits

Brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report $4.81 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $2.10 million and the highest is $7.50 million. Five Prime Therapeutics reported sales of $32.49 million during the same quarter last year, which would suggest a negative year over year growth rate of 85.2%. The business is expected to report its next earnings report on Tuesday, May 14th.

On average, analysts expect that Five Prime Therapeutics will report full year sales of $20.00 million for the current fiscal year, with estimates ranging from $7.30 million to $30.00 million. For the next year, analysts forecast that the firm will post sales of $51.67 million, with estimates ranging from $10.00 million to $150.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative return on equity of 44.55% and a negative net margin of 281.64%.

Several research analysts have recently weighed in on FPRX shares. Wedbush raised Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Thursday, January 17th. ValuEngine lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Monday, January 21st. BidaskClub raised Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 22nd. Finally, Cowen reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research report on Wednesday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Five Prime Therapeutics has an average rating of “Buy” and a consensus price target of $24.29.

Several hedge funds and other institutional investors have recently made changes to their positions in FPRX. Quantamental Technologies LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $58,000. Jane Street Group LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $110,000. Virtu Financial LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $113,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Five Prime Therapeutics by 456.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock worth $124,000 after buying an additional 10,895 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $140,000. Hedge funds and other institutional investors own 86.30% of the company’s stock.

Shares of FPRX stock traded up $0.43 during mid-day trading on Friday, hitting $12.40. The company’s stock had a trading volume of 599,600 shares, compared to its average volume of 287,570. Five Prime Therapeutics has a 52 week low of $7.84 and a 52 week high of $19.95. The firm has a market cap of $423.04 million, a PE ratio of -3.00 and a beta of 3.16.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

See Also: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.